BIG Peptide News (Must-Listen!): What Really Happened In Washington DC & A 7 Peptide Breakdown, With Dr. Matt Cook.

**Ben Greenfield** (0:00)
My name is Ben Greenfield, and on this episode of the Boundless Life podcast.

**Dr. Matt Cook** (0:04)
The complication rate from peptides is...

**Ben Greenfield** (0:08)
No doctor has ever really figured out in terms of like the whole picture.

**Dr. Matt Cook** (0:12)
These peptides are the way that our body communicates with itself. Has an effect kind of like basically what would happen if a cell was exercising.

**Ben Greenfield** (0:22)
So none of us need to exercise anymore.

**Dr. Matt Cook** (0:23)
The more that you exercise, the better.

**Ben Greenfield** (0:26)
Welcome to the Boundless Life with me, your host, Ben Greenfield. I'm a personal trainer, exercise physiologist, and nutritionist, and I'm passionate about helping you discover unparalleled levels of health, fitness, longevity, and beyond.
Hey, what's up? Quick intro to this podcast. An intro before the intro, actually. A few numbers were thrown around in this pretty important and pretty fascinating peptides podcast with Dr. Matt Cook. We sat down, he just started dropping knowledge bombs right and left. I did get my hands on some actual data, and he wanted to make sure I get the actual numbers out to you for the number of units administered of each of these different peptides with a shockingly low number of adverse events. So during these PCAC hearings back in Washington, DC, and we'll get into what that means, alphabet literacy during the podcast today, about 16 million BPC157 doses that were taken into consideration, about two and a half million TB500 doses, about 680,000 MOTS-C doses, about 3.6 million KPV doses, 100,000-ish Delta sleep-inducing peptide doses, about 210,000 epitalon doses, and about 350,000 CMax doses. So when we're talking about all of the studies or the administrations or the doses that were given, those were the actual numbers that were being investigated. So hopefully that helps, and I just wanted to, for you real nerds out there, for everybody who's putting your propeller hats on, why don't you take the deep dive? There you go. All right, show notes are at bengreenfieldlife.com/peptides2026. Let's go talk with my buddy, Matt Cook. Welcome to the show. I am out of my normal element because I traveled to a studio far away from home for this show because there has been a lot going on from a legislative standpoint in the whole world of peptides. Now, my guest today has been deeply involved in that scene and you may be familiar with him. He doesn't need much of an introduction because Dr. Matt Cook, I think this might be like your eighth time on the show. You've made it around quite a few times. And there's been a lot going on in DC the past few days. Matt just got back from DC and he's gonna share that with us and share what is happening right now in the peptide industry and what you can expect. All the show notes for today are going to be at bengreenfieldlife.com/peptides2026.
That's bengreenfieldlife.com/peptides2026.
I will also have some juicy links there, including one to a special cheat sheet, in case you can't remember everything that every peptide does, that Matt's gonna be spitting out today. So Matt, welcome back to the show for the umpteenth time.

**Dr. Matt Cook** (3:52)
Thank you so much. Great to be here.

**Ben Greenfield** (3:53)
So DC, you flew there. You just got back like, what, two or three days ago?

**Dr. Matt Cook** (3:58)
Yeah.

**Ben Greenfield** (3:59)
So why'd you go?

**Dr. Matt Cook** (4:00)
Well, so they have, the FDA has a committee called the Pharmacy Compounding Advisory Committee. And so this is the committee and their job is to review basically the data and the literature and make a decision about which drugs can be compounded. And if those drugs can be compounded, they're put on a bulk list.
And if they're put on that bulk list, then pharmacies can compound those for patients.

**Ben Greenfield** (4:29)
And when you say, I'm going to interrupt you a lot, by the way, when you say compounding, are you referring to those being available for just like the big pharmaceutical companies that we hear about, like GSK or Eli Lilly or whatever? Are we talking about like these smaller compounding pharmacists that a lot of people might be familiar with?

**Dr. Matt Cook** (4:51)
Yeah, so that would be what would be called a 503A compounding pharmacy.
And so then what they can do is they, once a compounding pharmacy can compound it, then what that means is there's a specific prescription for a specific patient. And then that compounding pharmacy can make that drug or that peptide and then distribute it to that individual patient.

**Ben Greenfield** (5:17)